Evidence map›Paper›PMID 39081462›Full record

ArticleMaterials today. Bio2024

Material extrusion 3D-printing technology: A new strategy for constructing water-soluble, high-dose, sustained-release drug formulations.

Zhiting Liu, Jiaying Huang, Danqiao Fang, Bohua Feng, Jianxu Luo, Peixuan Lei, Xiaoling Chen, Qingchun Xie, Meiwan Chen, Peihong Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhiting LiuState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China.
Jiaying HuangCenter for New Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Danqiao FangCenter for New Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Bohua FengGuangdong Province Engineering & Technology Research Center for Medical 3D Printer and Personalized Medicine, Guangzhou, 510006, China.
Jianxu LuoGuangdong Province Engineering & Technology Research Center for Medical 3D Printer and Personalized Medicine, Guangzhou, 510006, China.
Peixuan LeiCenter for New Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Xiaoling ChenCenter for New Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Qingchun XieCenter for New Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou, 510006, China.
Meiwan ChenState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China.
Peihong ChenDepartment of Pharmaceutics, China Pharmaceutical University, Nanjing, 210009, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The advantage of low-temperature forming through direct ink writing (DIW) 3D printing is becoming a strategy for the construction of innovative drug delivery systems (DDSs). Optimization of the complex formulation, including factors such as the printing ink, presence of solvents, and potential low mechanical strength, are challenges during process development. This study presents an application of DIW to fabricate water-soluble, high-dose, and sustained-release DDSs. Utilizing poorly compressible metformin hydrochloride as a model drug, a core-shell delivery system was developed, featuring a core composed of 96 % drug powder and 4 % binder, with a shell structure serving as a drug-release barrier. This design aligns with the sustained-release profile of traditional processes, achieving a 25.8 % reduction in volume and enhanced mechanical strength. The strategy facilitates sustained release of high-dose water-soluble formulations for over 12 h, potentially improving patient compliance by reducing formulation size. Process optimization and multi-batch flexibility were also explored in this study. Our findings provide a valuable reference for the development of innovative DDSs and 3D-printed drugs.

Indexed as

Core-shell systemDirect ink writingHigh drug loadingMaterial extrusionMetformin hydrochlorideSustained release

Identifiers

PMID39081462
PMCPMC11287018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.